Compare SG & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SG | SGMT |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.7M | 648.1M |
| IPO Year | 2021 | 2021 |
| Metric | SG | SGMT |
|---|---|---|
| Price | $10.08 | $8.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $8.08 | ★ $27.91 |
| AVG Volume (30 Days) | ★ 4.7M | 1.4M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $679,474,000.00 | $2,000,000.00 |
| Revenue This Year | $0.63 | N/A |
| Revenue Next Year | $7.98 | N/A |
| P/E Ratio | $12.93 | ★ N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $4.49 | $4.50 |
| 52 Week High | $10.64 | $11.45 |
| Indicator | SG | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 72.05 | 37.31 |
| Support Level | $6.24 | $6.21 |
| Resistance Level | $10.63 | $11.33 |
| Average True Range (ATR) | 0.39 | 0.56 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 72.11 | 16.37 |
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.